Subcutaneous injection of insulin can lead to problems such as hypoglycemia and edema.
Objective:
The purpose of this research was to evaluate the effect of oral insulin-coated trimethyl chitosan nanoparticles on control of glycemic status, IGF-1 and IGF-2 levels, and apoptosis in the hippocampus of rats with diabetes mellitus.
Methods:
Insulin-coated trimethyl chitosan nanoparticles were prepared by the polyelectrolyte complex method (PEC) method. Insulin loading content, loading efficiency, quantity and quality of particle size were evaluated. In vivo study was performed in different treatment groups of male Wistar rats with diabetes mellitus by insulin-coated trimethyl chitosan nanoparticles or subcutaneous injection of trade insulin. The duration of diabetes was eight weeks and the treatment was started after that time and continued for another two weeks. Body weight, fasting blood glucose (FBS), hippocampal apoptosis, and immunohistochemical (IHC) protein levels of IGF-1 and IGF-2 were assessed at the end of the experiments.
Results:
The size and polydispersity indexes were 533 nanometers and 0.533, respectively. Insulin coated trimethyl chitosan nanoparticles showed high loading efficiency (97.67% ) and loading content (48.83% ). The spherical shape of nanoparticle was confirmed by transmission electron microscopic (TEM). The amine, amide, ether and aliphatic groups were evaluated using FT-IR spectrophotometer which represented the correctness of the insulin coated trimethyl chitosan nanoparticles. Although the apoptotic index was not changed either by insulin-coated nano-particles or commercial insulin, in vivo results showed the efficacy of insulin-coated nanoparticles as well as commercial insulin in compensated weight loss, FBS and protein levels of IGF-1 and IGF-2.
Conclusions:
The present study showed the efficacy of insulin coated nanoparticle in oral route manner that can be tested in Phase I– III clinical trials. However, a behavioral study could reveal the efficacy of insulin-loaded nanoparticles in the improvement of cognitive changes through the modulation of IGF-1 and IGF-2 levels in the hippocampus.
AlberiniC.M, & ChenD.Y. (2012). Memory enhancement: Consolidation, reconsolidation and insulin-like growth factor 2. Trends in Neurosciences, 35(5), 274–283.
2.
AminS.N, YounanS.M, YoussefM.F, RashedL.A, MohamadyI. (2013). A histological and functional study on hippocampalformation of normal and diabetic rats. FResearch, 2, 151.
3.
ArbitE, & KidronM. (2009). Oral insulin: The rationale forthis approach and current developments. Journal of DiabetesScience and Technology, 3(3), 562–567.
4.
AttamaA.A, & Müller-GoymannC.C. (2007). Investigation ofsurface-modified solid lipid nanocontainers formulated with aheterolipid-templated homolipid. International Journal of Pharmaceutics, 334, 179–189.
5.
BayatA, LarijaniB, AhmadianS, JungingerH.E, & Rafiee-TehraniM. (2008). Preparation and characterization ofinsulin nanoparticles using chitosan and its quaternizedderivatives. Nanomedicine: Nanotechnology, Biology andMedicine, 4(2), 115–120.
6.
BiesselsG.J, KamalA, UrbanI.J, SpruijtB.M, ErkelensD.W, & GispenW.H. (1998). Water maze learning and hippocampalsynaptic plasticity in streptozotocin-diabetic rats: Effects ofinsulin treatment. Brain Research, 800(1), 125–135.
ChaudhuryA, & DasS. (2011). Recent advancement ofchitosan-based nanoparticles for oral controlled delivery of insulinand other therapeutic agents. AAPS Pharm Sci Tech, 12(1), 10–20.
9.
ChoiB.Y, KimI.Y, KimJ.H, LeeB.E, LeeS.H, KhoA.R, …SuchS.W. (2017). Administration of zinc pluscyclo-(His-Pro) increases hippocampal neurogenesis in rats duringthe early phase of streptozotocin-induced diabetes. International Journal of Molecular Sciences, 18(1), 73.
10.
ChoiS.W, BenzieI.F, MAS.W, StrainJ.J, & HanniganB.M. (2008). Acute hyperglycemia and oxidative stress: Direct cause andeffect?. Free Radical Biology and Medicine, 44(7), 1217–1231.
11.
des RieuxA, FievezV, GarinotM, SchneiderY.J, PreatV. (2006). Nanoparticles as potential oral delivery systems ofproteins and vaccines: A mechanistic approach. Journal of theControled Release, 116(1), 1–27.
ForlenzaO.V, DinizB.S, TeixeiraA.L, OjopiE.B, TalibL.L, MendonçaV.A, …GattazW.F. (2010). Effect ofbrain-derived neurotrophic factor Val66Met polymorphism and serumlevels on the progression of mild cognitive impairment. The World Journal of Biological Psychiatry, 11(6), 774–780.
14.
GispenW.H, & BiesselsG.J. (2000). Cognition and synapticplasticity in diabetes mellitus. Trends in Neurosciences, 23(11), 542–549.
15.
HosseininasabS, Pashaei-AslR, KhandaghiA.A, NasrabadiH.T, Nejati-KoshkiK, AkbarzadehA, …DavaranS. (2014). Synthesis, characterization, and in vitro studies of PLGA-PEG nanoparticles for oral insulin delivery. Biology & Drug Design, 84(3), 307–315.
16.
HanS.M, RussoA, CookJ.A, & MitchellJ.B. (1999). Amultidrug-resistant breast cancer line induced by weekly exposure todoxorubicin. International Journal of Oncology, 14, 273–279.
17.
HuiL, PeiD.S, ZhangQ.G, GuanQ.H, & ZhangG.Y. (2005). The neuroprotection of insulin on ischemic brain injury in rathippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation. Brain Research, 1052(1), 1–9.
18.
JintapattanakitA, JunyaprasertV.B, MaoS, SitterbergJ, BakowskyU, & KisselT. (2007). Peroral delivery of insulinusing chitosan derivatives: A comparative study of polyelectrolytenanocomplexes and nanoparticles. International Journal ofPharmaceutics, 342(1-20), 240–249.
19.
LannertH, & HoyerS. (1998). Intracerebroventricular administration of streptozotocin causes long-term diminutions inlearning and memory abilities and in cerebral energy metabolism inadult rats. Behavioral Neuroscience, 112(5), 1199–208.
LiZ.G, ZhangW, GrunbergerG, & SimaAA. (2002). Hippocampal neuronal apoptosis in type 1 diabetes. Brain Research, 946(2), 221–231.
22.
LiuJ.P, FengL, ZhangM.H, MaD.Y, WangS.Y, GuJ, (2013). Neuroprotective effect of Liuwei Dihuang decoction oncognition deficits of diabetic encephalopathy instreptozotocin-induced diabetic rat. Journal ofEthnopharmacology, 150(1), 371–381.
23.
LopesM, DerenneA, PereiraC, VeigaF, SeicaR, SarmentoB, & RiberioA. (2016). Impact of the in vitrogastrointestinal passage of biopolymer-based nanoparticles oninsulin absorption. RSC Advances, 6(24), 20155–20165.
24.
MaZ, LimT.M, & LimL.Y. (2005). Pharmacological activity ofperoral chitosan-insulin nanoparticles in diabetic rats. International Journal of Pharmaceutics, 293, 271–280.
25.
MahjubR, DorkooshF.A, AminiM, KhoshayandM.R, & Rafiee-TehraniM. (2011). Preparation, statistical optimization,and in vitro characterization of insulin nanoparticles composed ofquaternized aromatic derivatives of chitosan. AAPS Pharm SciTech, 12(4), 1407–1419.
26.
MahjubR, Heidari ShayestehT, RadmehrM, VafaeiS.Y, AminiM, DinarvandR, & DorkooshF.A. (2016). Preparation andoptimization of N-trimethyl-O-carboxymethyl chitosan nanoparticlesfor delivery of low-molecular-weight heparin. PharmceuticalDevelopment and Technology, 21(1), 14–25.
27.
MahjubR, RadmehrM, DorkooshF.A, OstadS.N, & Rafiee-TehraniM. (2014). Lyophilized insulin nanoparticlesprepared from quaternized N-aryl derivatives of chitosan as a newstrategy for oral delivery of insulin: In vitro, ex vivo and in vivo characterizations. Drug Development and Industrial Pharmacy, 40(12), 1645–1659.
MoselhyJ, WuX.Y, NicholovR, & KodariaK. (2000). In vitro characterization of interaction of poly(NIPAm/MAA)nanoparticles with proteins and cells. Journal of Biomaterials Science, Polymer Edition Edition, 11, 123–147.
30.
MuY, & GageF.H. (2011). Adult hippocampal neurogenesis and itsrole in Alzheimer’s disease. Molecular Neurodegeneration, 6, 85–85.
31.
NankaliM, KarimiJ, GoodarziM.T, SaidijamM, KhodadadiI, RazaviA.N.RahimiF. (2016). Increased expression of thereceptor for advanced glycation end-products (RAGE) is associatedwith advanced breast cancer stage. Oncololgy Research and Treatment, 39(10), 622–628.
PanY, LiY.J, ZhaoH.Y, ZhengJ.M, XuH, WeiG, …CuiF.D. (2002). Bioadhesive polysaccharide in protein deliverysystem: Chitosan nanoparticles improve theintestinal absorption of insulin in vivo. International Journal of Pharmaceutics, 249(1-2), 139–147.
34.
PrustyA.K, & SahuS.K. (2013). Development and evaluation of insulin incorporated nanoparticles for oral administration. ISRN Nanotechnology, 2013, 6. Article ID 591751
35.
SadeghiA.M, DorkooshF.A, AvadiM.R, SaadatP, Rafiee-TehraniM, & JungingerH.E. (2008). Preparation,characterization and antibacterial activities of chitosan,N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC)nanoparticles loaded with insulin using both the ionotropic gelationand polyelectrolyte complexation methods. International Journal of Pharmaceutics, 355, (1-2), 299–306.
36.
SakataK, MastinJ.R, DukeS.M, VailM.G, OveracreA.E, DongB.E., JhaS. (2013). Effects of antidepressant treatment onmice lacking brain-derived neurotrophic factor expression throughpromoter IV. The European Journal of Neuroscience, 37(11), 1863–1874.
37.
Santander-OrtegaM.J, CsabaN, AlonsoM.J, Ortega-VinuesaJ.L, & Bastos-GonzálezD. (2007). Stability andphysicochemical characteristics of PLGA, PLGA:poloxamer andPLGA:poloxamine blend nanoparticles: A comparative study. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 296(1-3), 132–140.
SonajeK, LinY.-H.JuangJ.-H., WeyS.-P., ChenC.-T., SungH.-W. (2009). In vivo evaluation of safety and efficacy of self-assembled nanoparticles for semoral insulin delivery. Biomaterials, 30, 2329–2339.
40.
TalbotK, WangH.Y, KaziH, HanL.Y, BakshiK.P, StuckyA, …ArnoldS.E. (2012). Demonstrated brain insulinresistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of Clinical Investigation, 122(4), 1316–1338.
41.
van der HeideL.P, RamakersG.M, & SmidtM.P. (2006). Insulinsignaling in the central nervous system: Learning to survive. Progress in Neurobiology, 79(4), 205–221.
42.
ViehofA, JavotL, BeduneauA, PellequerY, & LamprechtA. (2013). Oral insulin delivery in rats by nanoparticles prepared withnon-toxic solvents. International Journal of Pharmaceutics, 443(1-2), 169–174.
43.
VincentA.M, BrownleeM, & RussellJ.W. (2002). Oxidativestress and programmed cell death in diabetic neuropathy. Annals of the New York Academy of Science, 959, 368–83.
44.
WoitiskiC.B, NeufeldR.J, SoaresA.F, FigueiredoI.V, VeigaF.J, & CarvalhoR.A. (2012). Evaluation of hepatic glucosemetabolism via gluconeogenesis and glycogenolysis after oraladministration of insulin nanoparticles. Drug Development andIndustrial Pharmacy, 38(12), 1441–1450.
45.
WuZ.H, PingQ.N, WeiY, & LaiJ.M. (2004). Hypoglycemicefficacy of chitosan-coated insulin liposomes after oraladministration in mice. Acta Pharmacollogica Sinica, 25(7), 966–972.
